Researchers at Alynylam Pharmaceuticals in Cambridge, Massachusetts, developed an siRNA that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that typically binds and degrades ...

AstraZeneca's take on the PCSK9 inhibitor – an antisense drug ... competition – notably Novartis' small interfering RNA (siRNA) therapy Leqvio (inclisiran), which only needs to be administered ...

If those predictions are correct, AZ’s oral PCSK9 could have to contend with cut-price antibody drugs, a long-acting siRNA benefiting from marketing alongside Novartis’ blockbuster heart ...

Unlike inclisiran’s siRNA mechanism, VERVE-101 uses an mRNA-encoded adenine base editor plus a guide RNA that specifically targets the PCSK9 gene. Base editing alters a single base pair in the ...

PCSK9, which mediates post-translational destruction of LDL receptors, is raised in HoFH and is further raised by statins. LDL-C, following apheresis, quickly rebounds due to increased synthesis ...

在英克司兰的降脂作用中，siRNA技术的精妙之处在于，它能够靶向并特异性地抑制PCSK9（前蛋白转化酶枯草溶菌素9）蛋白的表达。PCSK9蛋白参与调节肝 ...

近年来，一种新型降脂药物——PCSK9抑制剂进入临床应用，药物通过皮下注射的方式给药，具有长效性和便捷性的优势，可以每2周到每6个月注射一次 ...

1月10日，恒瑞医药的一款抗PCSK9药物瑞卡西单抗获国家药监局批准上市，成为最新一款获批上市的国产靶向PCSK9的降脂药物。此前，已有6款PSCK9药物 ...